Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA accepts ProMetic's BLA for Ryplazim

Oct. 16, 2017

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

Oct. 5, 2017

FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib

Oct. 3, 2017

Ablynx reports phase III results for caplacizumab in aTTP

Oct. 2, 2017

Ruconest provides clinically meaningful relief of symptons in phase II study

Oct. 2, 2017

Alnylam Pharmaceuticals begins phase II study of cemdisiran in aHUS

Sep. 28, 2017

Topline results reported from Japanese phase II study of vadadustat in NDD-CKD

Sep. 27, 2017

Catalyst Biosciences' CB-2679d awarded FDA orphan drug status for hemophilia B

Sep. 27, 2017

Dova Pharmaceuticals submits NDA in U.S. for avatrombopag

Sep. 26, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...